Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liquid-biopsy Informed Platform Trial in CDK4/6i-Resistant ER+/HER2- Metastatic Breast Cancer
NCT05601440Phase 2Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jun 2023
- Primary completion
- Dec 2027
- Modality
- Reversible Covalent Inhibitors, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of lunresertib, niraparib, camonsertib, luvixasertib, ocifisertib in breast cancer, sponsored by Canadian Cancer Trials Group. Started Jun 2023; status: recruiting.
02
Drugs
lunresertibniraparibcamonsertibluvixasertibocifisertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05601440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601440.